Oric raises $53 million series B

Oric Pharmaceuticals Inc. (South San Francisco, Calif.) raised $53 million in a series B round with The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. Oric's unnamed lead compound is a glucocorticoid receptor antagonist that is in preclinical development for castration-resistant prostate cancer (CRPC). ...